Starpharma Holdings Limited · ASX:SPL
Starpharma — Biotech Capital Portfolio Showcase (February 2007)
37 slides from Starpharma's conference presentation, Feb 7, 2007
Slide 1: Investor Presentation — Biotech Capital Portfolio Showcase
o starpharma Investor Presentation — Biotech Capital Portfolio Showcase Dr Jackie Fairley, CEO of Starpharma Holdings Lid (ASX:SPL, USOTC:SPHRY) will be presenting at the second Biotech Capital Portfolio Showcase, to be held in Melbourne, Australia at 6.30pm on 7 February 2007. A copy of the slide p
Slide 2: Biotech Capital Investor Showcase
starpharma Siotech Capital levestor Shewease February 7 2007 Starpharma Holdings Limited AGMIESP E, USOTCISPHRY Op Jackie Fairley CEO
Slide 3: Forward-looking statements
o starpharma This document contains certain forward-looking statements, relating to Starpbharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”. “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “
Slide 4: Outline
Outline o starp harma 1. Investment Highlights 2. Company Overview 3. VivaGel™ 4. Product Pipeline 5. Conclusion
Slide 5: 1. Investment Highlights
7. Investment starpharma
Slide 6: Key Investment Highlights
Ntey investment Mightights o starpharma till Compelling competitive advantages Endorsement from key health agencies: - Significant funding support received from NIH (>$26M) - The only microbicide with support for genital herpes HIV and genital herpes at epidemic proportions Herpes rates Europe ~ 15-
Slide 7: 2. Company Overview
starpharma
Slide 8: Company Overview
Gompany Overview o starpharma = World leader in the development of dendrimer nanotechnology products for pharmaceutical and life- sciences # Lead product VivaGel™ is being developed (under IND) as a microbicide to prevent HIV and Genital Herpes - US$20.3m NIH contract to develop VivaGel™ for HIV - F
Slide 9: Company Structure
o Company Structure starpharma 100.0% 100.0% Dend ¢ Nanotechnologies ~~ (ONT) = 36 employees based in Melbourne, Australia * 16 employees based in Michigan, USA = Uses dendrimer technology to discover, ® Leading developer and provider of advanced develop and commercialise pharmaceuticals dendrimers
Slide 10: ADR (SPHRY) Program and US Shareholding
ADR (SPHRY) Program and US Shareholding o starpharma Starparma’s ADR program has been extremely successful since launch in January 2005 - Growth of 112% in ADRs issued in the past 12 months - Average monthly growth of 6.4% Traded by major brokers including Merrill Lynch, Credit Lyonnais, Natexis Ble
Slide 11: Starpharma: Technology Overview
Starpharmna: Technology Qverview o starpharma Unique Characteristics of Dendrimers: Commercial Advantages of Dendrimers: Vim Precisely defined, synthetic macromolecules (1-10nm) Precisely defined surface topology Can be designed to optimize potency, pharmacokinetics and localization; heat stable or
Slide 12: 3. VivaGel
3. VivaGel™ starpharma
Slide 13: Herpes and HIV: Global Medical Problems
S Herpes and MIW: Global Medical Problems starpharma * Major health burden in both developed and = Recurrent, lifelong viral infection developing countries = Estimated to infect between 15-25% of adults in * 39 million people living with HIV; every day 7,000 developed countries women are newly infec
Slide 14: VivaGel — Lead Product for Prevention of STIs
o VivaGel™ — Lead Product for Prevention of 83 ls stargharma * VivaGel™ is a vaginal microbicide being developed to prevent sexually transmitted infections in women VivaGel™ Applicators — Currently being developed under two INDs for the prevention of HIV and genital herpes » Gel-based formulation wi
Slide 15: VivaGel — Product Features and Performance
VivaGel"™ — Product Features and Performance o starp harma Female controlled, discreet and convenient activity Contraceptive activity (in animals) Compelling competitive advantages: efficacy; non-irritant; broad Market research indicates microbicide gels will have good uptake Potent activity against
Slide 16: VivaGel
o VivaGel™ starpharma « Compelling competitive advantages: HIV& Herpes efficacy; non-irritant; broad activity * US$20.3m non-dilutive NIH development funding for HIV; the only microbicide with NIH support for Genital Herpes = FDA Fast Track Status for HIV » Successfully completed Phase 1 trial in hu
Slide 17: Welcome to the VivaGel Clinic, Kenya
o starpharma ribu “Welcome” to the VivaGel Clinic, Kenya Medical Research Insti
Slide 18: AIDS Marathon, Kisumu, Kenya
o starpharma a AIDS Marathon, Kisumu, Kenya, Decem 2006 47
Slide 19: Commercial Opportunity for Microbicides
o Gommercial Goportunity for Microbicides starpharma = US genital herpes and HIV costs ~18 billon pa. Estimated Market for microbicides in Developed Countries » Large, addressable markets = Increasing market support for products a ou - US government firmly committed to development of safe 2.5% 265 7
Slide 20: HSV-2 Prevention
] H&S-2 Prevention starpharma Time to Translate New Knowledge into Practice: A Call for a National Genital Herpes Control Program Edward W. Hook'? and Peter Leone™* ‘University of Alabama at Birmingham and “Jefferson County Department ef Health, Birmingham; "University af North Carolina at Chapel Hi
Slide 21: 4. Product Pipeline
4, Product Pipeline
Slide 22: Pipeline: Balanced for Risk
o Pipeline: Balanced for Rist starpharma Prooi of Concept Pharmaceutical & Medical Products VivaGel™ » HSV-2 prevention >» HIV prevention » condoms coating & other line extensions ADME Engineering™ » Therapeutic protein PK optimisation Clinical Trials Drug Delivery - Small Molecules » Cancer therape
Slide 23: Early Opportunities
Early Opportunities o starpharma Marketed Dendrimer PrioFect™ siRNA Materials Science / Products transfection agents Industrial Applications Value Capture Current Early 2007 2007 / 08 Horizon Existing product sales and Transfection reagent market: licensed dendrimer royalty $120M growing by 15-18% p
Slide 24: PrioFect and siRNA transfection
o Privfect™ and siRhtA transtection starpharma Adding siRNA to a cell can “turn off” production of specific cellular proteins “The discovery of RNA interference (RNAI) may weil be one of the transforming events in biology in the past decade” Natute The discovery of RNAi has already had an immense im
Slide 25: PrioFect and siRNA transfection
o Privfect™ and siRhtA transtection starpharma + Enhances uptake of siRNA (and DNA) into cells « 2potential applications: « Research reagent ° In vivo . SIRNA / DNA Charge Association Endocytosis Competitive Advantages + Superior efficacy through reagent size control + Gell-specific targeting - Phar
Slide 26: 5. Conclusion
5. Conclusion starpharma
Slide 27: Investment Summary
o lavestment Summary starpharma v Microbicides have been identified as the solution to the HIV/STI pandemic v¥ Starpharma has a leading microbicide (VivaGel™) in development for prevention of HIV and genital herpes v VivaGel™ has achieved significant milestones and support - Fast track status grante
Slide 28: Further information
& starpharma Further informations Jackie Fairley CEO POVSER Gaal OD
Slide 29: Appendix
starpharma
Slide 30: VivaGel: Animal Efficacy results
WVivaGel™: Animal Efficacy results o starp harma SHIV/HIV Protection Cornbined Results Ned Ned Percentage of Animals Protected from SHIV Infecton AIDS Research & Human Retroviruses, 21, pp207-213, 2006. Advantage: VivaGel™ is NOT a surfactant Surfactants damage epithelial cells INCREASING the chance
Slide 31: VivaGel: Significant Advantages Over Competitors
VivaGelr™ ; Significant Advantages Over Competitors o starp harma | Competitor Category | _ KeyDisadvantages | VivaGel™ is the only microbicide being developed to. prevent genital herpes. / : Surfactants/Detergents | Ulceration possible Potential increased risk of infection No surfactant properties
Slide 32: VivaGel: Potent Contraceptive Activity in Rabbits
o VivaGel”™ » Potent Contraceptive Activity in Rabuits stargharma » Recent study has shown that SPL7013, the active ingredient in ; ; ; its VivaGel™, exhibits a potent *oneation of Vaginal Soe an seeelave teraiyin® contraceptive effect in rabbits Active Gel-Treated Rabbits Compared with HEC Control
Slide 33: Portfolio of Opportunities
o Portfolio of Opportunities starpharma | 32
Slide 34: Pipeline: Drug Delivery & PK Modification of Protein Therapeutics
@ Pipeline: Drug Delivery & PH Modification of Protein Therapeutics starpharma Plasma concentration-time profile in male SD rats for PEGylated poly-L-lysine dendrimers -~ 100000 = 2 3 8 e “ a5 Ly Saal PEG yeaa £ e °% @ Z t,, = 0.6h 5 10000) og } =~ © t,, = 0.7h E é ® ; 5 6 t,, = 9.5h s : Lys, _(PEGs
Slide 35: RNAi therapeutics
@ ANAT therapeutics starpharma Ph TT AMD & DME anti-inflammatories & anti-infectives Ph 1 2006 (RSV) pandemic flu, spinal cord injury, Parkinson's, cysti¢ fibrosis, hypercholesterolemia, neuropathic pain Ph TL AMD (w/ Allergan) Asthma, RSV, Huntington's, viral hepatitis, diabetes, oncology, dermatol
Slide 36: Partnerships
o Partnerships starp harma DADE BEHRING i) DHARMACON Grolmnon sGobren Rereavch Land Systems hava TegHMaLOSEES @ avoaice lumera Research) ee ne ‘ “ Xv Wersity INSTITUTE FOR SOLDIER MANCTECNOLORIES , aN INSTATE a Etfabrication sess Facility CALTECH Co aborators -
Slide 37: Extensive IP Portfolio
o Extensive (P Portfolio starpharma » With the acquisition of DNT, Starpbharma has the most comprehensive dendrimer IP portfolio for a broad spectrum of products and applications: ~ VivaGel ™ (Composition and Application) ~ Drug delivery (Applications) ~ Priostar™ dendrimers (Composition) ~ Poly-lys
Starpharma Holdings — Biotech Capital Portfolio Showcase (February 2007) on 6ix